

Remarks


The Examiner has required a restriction in the above case to one of Groups I-IV. Applicants elect Group III, claims 6, 7, and 10. Applicants have withdrawn claims 1-5 and 8-9 as being drawn to non-elected subject matter. No new matter has been introduced. Applicants reserve their right to file a divisional application directed to material that is withdrawn due to the restriction requirement.

The Examiner has also requested the applicants elect a single compound within the scope of the elected claims. Applicants designate the compound of Example 3, i.e., in formula (VIII), where R12 is Fmoc (fluorenylmethoxycarbonyl) and R13 is Boc (tert butoxycarbonyl).

In view of the foregoing remarks, further and favorable consideration of the present application and the allowance of all pending claims are respectfully requested. The Examiner is also invited to contact the undersigned should the Examiner believe that such contact would expedite prosecution of the present application.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: April 27, 2007